dacuronium bromide

{{short description|Chemical compound}}

{{Drugbox

| Verifiedfields =

| Watchedfields =

| verifiedrevid =

| IUPAC_name = [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-17-Hydroxy-10,13-dimethyl-2,16-bis(1-methylpiperidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl] acetate;dibromide

| image = Dacuronium bromide.svg

| width = 250

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref =

| CAS_number = 27115-86-2

| CAS_supplemental =

| class =

| ATC_prefix =

| ATC_suffix =

| ATC_supplemental =

| PubChem = 14029396

| IUPHAR_ligand =

| DrugBank_Ref =

| DrugBank =

| ChemSpiderID_Ref =

| ChemSpiderID = 16736917

| UNII = 33482245B6

| KEGG =

| ChEBI =

| ChEMBL = 3138544

| C=33 | H=58 | Br=2 | N=2 | O=3

| SMILES = CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1[N+]4(CCCCC4)C)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5O)[N+]6(CCCCC6)C)C.[Br-].[Br-]

| StdInChI_Ref =

| StdInChI = 1S/C33H58N2O3.2BrH/c1-23(36)38-30-20-24-12-13-25-26(33(24,3)22-29(30)35(5)18-10-7-11-19-35)14-15-32(2)27(25)21-28(31(32)37)34(4)16-8-6-9-17-34;;/h24-31,37H,6-22H2,1-5H3;2*1H/q+2;;/p-2/t24-,25+,26-,27-,28-,29-,30-,31-,32-,33-;;/m0../s1

| StdInChIKey_Ref =

| StdInChIKey = SUKULMJPMHYWKC-GMMLHHOXSA-L

| synonyms = NB-68; 17β-Hydroxypancuronium bromide; 3α-(Acetyloxy)-17β-hydroxy-2β,16β-bis(1-methylpiperidinium-1-yl)-5α-androstane dibromide; 2β,16β-Dipiperidino-5α-androstane-3α,17β-diol 3α-acetate dimethobromide

}}

Dacuronium bromide (INN, BAN) (developmental code name NB-68) is an aminosteroid neuromuscular blocking agent which was never marketed.{{cite book | vauthors = Elks J |title= The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies |url= https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA647 |date=14 November 2014 |publisher= Springer |isbn=978-1-4757-2085-3 |pages=647–}}{{cite book | vauthors = Morton IK, Hall JM |title= Concise Dictionary of Pharmacological Agents: Properties and Synonyms |url= https://books.google.com/books?id=tsjrCAAAQBAJ&pg=PA90 |date=6 December 2012 |publisher= Springer Science & Business Media |isbn= 978-94-011-4439-1 |pages=90–}}{{cite book |title= Progress in Medicinal Chemistry |url= https://books.google.com/books?id=wesIAirSEDkC&pg=PA102 |date=1 January 1979 |publisher= Elsevier |isbn= 978-0-08-086264-4 |pages=102–}}{{cite book | vauthors = Maclagan J | chapter = Competitive neuromuscular blocking drugs. | title = Neuromuscular Junction | date = 1976 | pages = 421–486 | publisher = Springer | location = Berlin, Heidelberg | chapter-url= https://books.google.com/books?id=D-DtCAAAQBAJ&pg=PA421 |isbn=978-3-642-45476-9 }}{{cite book| vauthors = Kharkevich DA |title=New Neuromuscular Blocking Agents: Basic and Applied Aspects |url= https://books.google.com/books?id=cyD0CAAAQBAJ&pg=PA201|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-3-642-70682-0|pages=201–202,213}} It acts as a competitive antagonist of the nicotinic acetylcholine receptor (nAChR).